METHOCARBAMOL Drug Interactions
Also known as: Methocarbamol
Methocarbamol is a medication used to help relieve discomfort from acute, painful muscle and bone conditions, often alongside rest and physical therapy. It works by affecting the central nervous system to reduce muscle spasms and pain, though it doesn't directly relax the muscles themselves.METHOCARBAMOL has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment, including dizziness and ataxia. In severe cases, this interaction can lead to coma, respiratory arrest, and death. Impaired motor function can also increase the risk of falls and accidents.
Mechanism
Both buprenorphine, an opioid partial agonist, and methocarbamol, a centrally acting muscle relaxant, exert depressant effects on the central nervous system (CNS). The coadministration of these agents leads to an additive pharmacological effect, significantly enhancing CNS depression. This synergistic action can compromise vital functions regulated by the CNS.
Clinical Management
Concomitant use should generally be avoided. If coadministration is deemed necessary, initiate buprenorphine at the lowest effective dose and titrate slowly, and consider reducing the methocarbamol dose. Closely monitor patients for signs of respiratory depression, sedation, and altered mental status, especially during initiation or dose escalation of either drug. Educate patients on the risks and advise against operating heavy machinery or driving.
This additive CNS depression can manifest as profound sedation, dizziness, confusion, and psychomotor impairment. Most critically, it significantly increases the risk of severe respiratory depression, which can be life-threatening. Patients may also experience hypotension and impaired coordination.
Mechanism
Fentanyl, an opioid analgesic, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia, sedation, and respiratory depression. Methocarbamol, a centrally acting muscle relaxant, also exerts its effects through general CNS depression, though its precise mechanism is not fully understood. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use of fentanyl and methocarbamol should generally be avoided due to the high risk of severe CNS and respiratory depression. If co-administration is deemed absolutely necessary, initiate both medications at the lowest effective doses and titrate cautiously. Closely monitor patients for signs of respiratory depression, sedation, and altered mental status, especially during initiation or dose adjustments. Consider alternative pain management or muscle relaxant strategies if possible.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Other effects include hypotension and increased risk of falls.
Mechanism
Oxycodone is an opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Methocarbamol is a centrally acting muscle relaxant that also causes generalized CNS depression, though its exact mechanism is not fully understood. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxycodone and methocarbamol if possible. If co-administration is necessary, initiate therapy with the lowest effective doses of both medications and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery.
Patients may experience profound sedation, dizziness, confusion, and impaired cognitive function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Additionally, motor incoordination and falls are more likely, especially in elderly patients.
Mechanism
Both morphine, an opioid analgesic, and methocarbamol, a centrally acting muscle relaxant, exert their primary effects by depressing the central nervous system (CNS). When co-administered, their individual CNS depressant actions are additive, leading to an enhanced overall depressant effect. This includes synergistic depression of respiratory drive, sedation, and psychomotor function.
Clinical Management
Concomitant use should generally be avoided. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an elevated risk of respiratory depression, which can be life-threatening. This combination can also significantly impair the ability to operate machinery or drive.
Mechanism
Both tramadol and methocarbamol exert central nervous system (CNS) depressant effects. Tramadol's mechanism involves opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, while methocarbamol acts as a general CNS depressant. The co-administration leads to an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, use the lowest effective doses for the shortest duration, and monitor patients closely for signs of CNS and respiratory depression. Educate patients about the risks and advise against activities requiring mental alertness.
Patients may experience profound sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Impaired motor function and coordination can also increase the risk of falls and accidents.
Mechanism
Both codeine sulfate, an opioid analgesic, and methocarbamol, a centrally acting muscle relaxant, exert their primary effects through central nervous system (CNS) depression. The co-administration of these agents leads to an additive depressant effect on the CNS, potentiating their individual sedative and respiratory depressant properties.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, initiate therapy with the lowest effective doses of both drugs and titrate carefully, monitoring closely for signs of CNS and respiratory depression. Educate patients about the risks, including avoiding driving or operating heavy machinery, and provide naloxone for at-risk patients.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory arrest. The combination can also exacerbate cognitive impairment and decrease the level of consciousness.
Mechanism
Both methadone, an opioid analgesic, and methocarbamol, a centrally acting muscle relaxant, exert depressant effects on the central nervous system (CNS). This interaction is primarily pharmacodynamic, as their combined use leads to an additive or synergistic increase in CNS depression. Methadone acts on opioid receptors, while methocarbamol's exact mechanism is not fully understood but involves general CNS depression.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks, advise against operating machinery or driving, and instruct them to seek immediate medical attention for severe drowsiness or breathing difficulties.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. Symptoms can include excessive drowsiness, dizziness, confusion, difficulty breathing, and slowed or shallow respiration. The risk of falls and accidental injury is also significantly increased.
Mechanism
Both hydromorphone, an opioid agonist, and methocarbamol, a centrally acting muscle relaxant, exert depressant effects on the central nervous system (CNS). The concomitant use of these agents leads to an additive pharmacological effect, increasing the overall CNS depression. This synergy primarily affects neuronal activity in the brain and spinal cord.
Clinical Management
Avoid concomitant use of hydromorphone and methocarbamol if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of CNS and respiratory depression. Educate patients and caregivers about the risks and instruct them to seek immediate medical attention if symptoms of severe sedation or respiratory compromise occur.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory arrest. Symptoms such as dizziness, confusion, and difficulty breathing should be closely monitored.
Mechanism
Oxymorphone, an opioid agonist, exerts its primary effects through binding to mu-opioid receptors in the central nervous system (CNS), leading to analgesia, sedation, and respiratory depression. Methocarbamol is a centrally acting skeletal muscle relaxant whose mechanism of action is not fully elucidated but involves general CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxymorphone and methocarbamol if possible. If co-administration is necessary, initiate both drugs at the lowest effective dose and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise. Dizziness, confusion, and decreased level of consciousness are also common.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist activity and norepinephrine reuptake inhibition. Methocarbamol is a central nervous system (CNS) depressant that acts as a muscle relaxant, though its precise mechanism is not fully understood. Concomitant use results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tapentadol and methocarbamol if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and monitor patients closely for signs of CNS depression, especially during initiation or dose escalation. Educate patients about the risks and advise against driving or operating heavy machinery.
For complete prescribing information:
View full METHOCARBAMOL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.